CULLINAN THERAPEUTICS, INC. Proceeds from Stock Options Exercised
CULLINAN THERAPEUTICS, INC. (CGEM) reported Proceeds from Stock Options Exercised of $1.59 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2022-05-16
- CULLINAN THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2022-03-31 was $1.59M.
- CULLINAN THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2021-12-31 was $2.70M.
- CULLINAN THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2021 was $3.28M, a 5758.93% increase from fiscal 2020.
- CULLINAN THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2020 was $56.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2022-03-31 | $1.59M 10-Q · filed 2022-05-16 | $4.29M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2021-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.28M 10-K · filed 2022-03-17 | ||
| 2021-09-30 | $579.00K 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | $56.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |